Carolyn Bertozzi’s new biotech Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T Wed Th F 20 November, 2024

John Carroll talks to industry execs about the FDA, the new guard, funding and more — how are they planning for 2025? Tune in — register today.

presented by Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

news Sage reports Phase 2 failure in Huntington's disease, ends drug's development Pfizer taps oncology head Boshoff as Dolsten's chief scientific officer successor Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy Exclusive: Former Pfizer commercial chief Angela Hwang to join Flagship

Dec 03 12:30pm ET From AI to IRA to GLP-1s: Unpacking the major healthcare trends at #JPM2025 sponsored by Real Chemistry Dec 04 12:00pm ET The pragmatic shift: Designing trials that fit the real world sponsored by Flatiron Dec 09 1:00pm ET Accelerating drug discovery with an end-to-end imaging data management platform sponsored by Flywheel Dec 12 11:00am ET Accelerating discovery in targeted protein degradation: Innovative approaches to degrader screening sponsored by Bio Techne

Biopharma’s elite are descending upon JPM, and our event is your insider’s guide to the industry. Join conversations with dealmakers, investors, and industry titans. The Endpoints Hub is your oasis amidst the JPM frenzy. Secure your spot now — Early Bird is ending soon.

Endpoints Pharma GSK plots regulatory filings for PBC itch after positive Phase 3 readout Ahead of adcomm, FDA raises safety questions for AstraZeneca’s reversal agent for life-threatening bleeds Drugmakers 'not doing everything that they could' to widen global access, new report finds NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend In Focus Lawmakers are poking holes in pharma's favorite new way to market medicines

in case you missed it 1. Merck finally has subcutaneous Keytruda results, and it's going to regulators 2. J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster 3. Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success 4. Former NCI director teams up with serial entrepreneur for $70M VC fund targeting 'super-early' science 5. Bristol Myers takes on autoimmune diseases with cell therapy, plus new data from Cabaletta and Kyverna